Consistency of Treatment Effect across Regions in Multiregional Clinical Trials, Part 2: Monitoring, Reporting, and Interpretation

Drug Information Journal

Volumn 45, Issue 5, 2011, Pages 603-608

  Gallo, Paul ^a   Chen, Joshua ^b   Quan, Hui ^c   Menjoge, Shailendra ^a   Luo, Xiaolong ^a   Tanaka, Yoko ^a   Li, Gang ^a   Ouyang, S Peter ^a   Binkowitz, Bruce ^b   Ibia, Ekopimo ^b   Talerico, Steven ^a   Ikeda, Kimitoshi ^a  

^a Novartis ^*  (Japan)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Global Health Outcomes and Market Access   (United States)

Author keywords

Consistency; Empirical shrinkage; Multiregional trial; Treatment by region interaction; Trial monitoring

Indexed keywords

METOPROLOL; NEW DRUG;

ARTICLE; AUTHORITY; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); DRUG FATALITY; HEALTH CENTER; HUMAN; INFORMATION PROCESSING; METHODOLOGY; NULL HYPOTHESIS; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PRIORITY JOURNAL; PROCESS MONITORING; PROGNOSIS; RANDOM SAMPLE; SAMPLE SIZE;

EID: 84862257793     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286151104500610     Document Type: Article

References (15)

1. ChenJQuanHGalloPOuyangSPBinkowitzB. An adaptive strategy for assessing regional consistency in multi-regional clinical trials. Technical Report #138, Merck Research Laboratories. March 2011.
2. US Food and Drug Administration. Draft guidance for industry: adaptive design clinical trials for drugs and biologics. February 2010.
3. Wang SJ,O'Neill RT,Hung HMJ.Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset.Pharm Stat. 2007;6:227-244.
4. Luo X,Shih WJ,Ouyang SP,Delap RJ.An optimal adaptive design to coordinate local regulations with simultaneous global development.Pharm Stat. 2010;9:179-189.
5. O'Shea JC,DeMets DL.Statistical issues relating to international differences in clinical trials.Am Heart J. 2001;142:21-28.
6. Ellenberg SS,Fleming TR,DeMets DLData Monitoring Committees in Clinical Trials: A Practical Perspective. New York: Wiley; 2002:.
7. Chen J,Quan H,Binkowitz B, et al.Assessing consistent treatment effect in a multi-regional clinical trial: A systematic review.Pharm Stat. 2010;9:242-253.
8. Marschner IC.Regional differences in multinational clinical trials: Anticipating chance variation.Clin Trials. 2010;7:147-156.
9. QuanHLiMShihWJEmpirical shrinkage estimator for consistency assessment of treatment effects in multi-regional clinical trials. Sanofi-Aventis Technical Report #48. 2011.
10. Hung HMJ,Wang SJ,O'Neill RT.Consideration of regional difference in design and analysis of multi-regional trials.Pharm Stat. 2010;9:173-178.
11. Li Z,Chuang-Stein C,Hoseyni C.The probability of observing negative subgroup results when the treatment effect is positive and homogenous across all subgroups.Drug Inf J. 2007;41:47-56.
12. Wedel H,DeMets D,Deedwania P, et al.Challenges of subgroup analyses in multinational clinical trials: Experiences from the MERIT-HF.Am Heart J. 2001;142:502-511.
13. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF).Lancet. 1999;353:2001-2007.
14. Akkerhuis KM,Deckers JW,Boersma E, et al.Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes.Eur Heart J. 2000;21:371-381.
15. Blair JEA,Zannad F,Konstam MA, et al.Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure.J Am Coll Cardiol. 2008;52:1640-1648.